Cancel
Adam D. Levy
Investor Relations and Corporate Affairs
@
Acrivon Therapeutics
kw.1w5k@hshugkf.h5q
Sign up to see email
Known information
- Led Investor Relations at multiple biotech companies, including Zentalis Pharmaceuticals and Turning Point Therapeutics
- Led Corporate Strategy at Gilead Sciences, directing the development of a new set of corporate ambitions and strategies
- Served as Vice President of Corporate Strategy at Alexion Pharmaceuticals, delivering the company’s first ever board-endorsed strategic plan
- Led multiple teams at McKinsey and Company as Engagement Manager, focusing on helping large pharma companies develop and implement growth strategies
- Received an MBA from the Kellogg School of Management at Northwestern University
- Earned a PhD in Molecular Biology from the University of Illinois at Chicago
- Holds a BS in Genetics from the University of Illinois at Urbana-Champaign
About Acrivon Therapeutics
Acrivon Therapeutics develops precision oncology medicines using a proprietary proteomics-based platform, with its lead candidate ACR-368 in a Phase 2 trial for multiple tumor types.
Report inaccurate information
